Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by bionicjoeon Mar 06, 2019 2:38pm
88 Views
Post# 29451194

RE:RE:RE:RE:Volume versus increase in share price - "don't like it"

RE:RE:RE:RE:Volume versus increase in share price - "don't like it"
floatinketucky wrote: hi bionicjoe. I disagree with you on  it all... lol.  Without the shelf prospectues they cannot do a pp. That's why they closed the prospectus.   Remember back in 2017 you kept saying PP  PP PP. and I disagreed then. Still do now and the prospectus is closed to finalize the debate.

Can anyone elese advise on this?




Floatinketucky, the shelf prospectus and the guidelines under which it would operate no longer applies. In it a company has the advantage of conducting a PP or a series of PP's on short notice since the instrument has already been voted in favor of by shareholders. From my experience a regular PP takes over a month to complete from start to finish whereas a shelf prospectus PP can be done with only a few days notice. It stands to reason that if the shelf prospectus is no longer in effect then the company can revert back to the traditional PP. Why the OSC made the announcement on TLT's Sedar listing I can't explain. It came with a reference number but when doing a search on the government site nothing came up for me. You might have to wait until the next MD&A for an explanation. 

I don't recall but if I did say a PP was coming I didn't take into account the old cash them or lose them warrants that came due in the spring of 2018 and the small PP that was done later in the year. Enough for everyday expenses but certainly not sufficient to pay for a phase 2 trial and that's what I assume I was getting at  IMO, it still is an option for the company if they can't interest a strategic partner to fund the phase 2 trial.



Bullboard Posts